Specialities

Specialities

Adrenal Disorders
Bone Disorders
Cardiovascular Risk
COVID-19
Diabetes
Endocrine Oncology
General Endocrinology
Kidney Disorders
Obesity
Pediatric Endocrinology
Pituitary Disorders
Reproductive Endocrinology
Thyroid Disorders
Liver Disorders
Rare Disease Day
Search

Trending Topic
3 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Foreword: touchREVIEWS in Endocrinology 22.1

Welcome to the summer 2026 issue of touchREVIEWS in Endocrinology. In this issue, we bring together articles that reflect the evolving complexity of endocrine and metabolic disease, while highlighting the growing importance of patient-centred care, translational science and interdisciplinary management. We open the issue with a timely commentary by Huajing Ni et al., which examines […]

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
touchMEETING HIGHLIGHTS

Omnipod 5 Automated Insulin Delivery System In Action: Conquering Challenging Cases to Achieve Real-World Success

Topics Covered:
Diabetes Pediatric Endocrinology
Open Nav

Video

Introduction

Activity overview and faculty introduction
Severine Liabat from Insulet provides a brief introduction to this activity on real-world case studies of Omnipod 5 use, and the faculty.
Start Time: 0:00

Important considerations for choosing an AID

Choosing an AID
Cari Berget introduces key features of the Omnipod 5 and clinical data supporting its use in patients with type 1 diabetes.
Start Time: 6:13

Case 1 – adult patient with T1D

Impact of Omnipod 5 in case 1
Cari Berget describes the impact of Omnipod 5 in an adult with type 1 diabetes and a history of inconsistent use of continuous glucose monitoring and carb counting.
Start Time: 16:49

Case 2 – adolescent patient with T1D

Impact of Omnipod 5 in case 2
Dr Fiona Campbell describes the impact of Omnipod 5 in an active adolescent with type 1 diabetes and a history achieving 90% or more time in glycemic range.
Start Time: 25:59

Case 3 – pediatric patient with T1D

Impact of Omnipod 5 in case 3
Dr Jody Grundman describes the impact of Omnipod 5 in a pediatric patient with type 1 diabetes and growth concerns from sub-optimal glycemic control.
Start Time: 44:50

Empowering clinicians and families

Resources
Severine Liabat provides insights into features of Omnipod 5 that can turn data into actionable insights, and resources for clinicians.
Start Time: 59:44
touchENDOCRINOLOGY

Check your Inbox

We've sent your certificate

Back to Activity
Close Popup
touchENDOCRINOLOGY

Thank you
for your Feedback!

Back to Activity
Close Popup

Video Navigation

Video

Introduction

Activity overview and faculty introduction
Severine Liabat from Insulet provides a brief introduction to this activity on real-world case studies of Omnipod 5 use, and the faculty.
Start Time: 0:00

Important considerations for choosing an AID

Choosing an AID
Cari Berget introduces key features of the Omnipod 5 and clinical data supporting its use in patients with type 1 diabetes.
Start Time: 6:13

Case 1 – adult patient with T1D

Impact of Omnipod 5 in case 1
Cari Berget describes the impact of Omnipod 5 in an adult with type 1 diabetes and a history of inconsistent use of continuous glucose monitoring and carb counting.
Start Time: 16:49

Case 2 – adolescent patient with T1D

Impact of Omnipod 5 in case 2
Dr Fiona Campbell describes the impact of Omnipod 5 in an active adolescent with type 1 diabetes and a history achieving 90% or more time in glycemic range.
Start Time: 25:59

Case 3 – pediatric patient with T1D

Impact of Omnipod 5 in case 3
Dr Jody Grundman describes the impact of Omnipod 5 in a pediatric patient with type 1 diabetes and growth concerns from sub-optimal glycemic control.
Start Time: 44:50

Empowering clinicians and families

Resources
Severine Liabat provides insights into features of Omnipod 5 that can turn data into actionable insights, and resources for clinicians.
Start Time: 59:44

Activity Overview

Faculty & Disclosures

Overview
Faculty & Disclosures

Overview

Many patients with type 1 diabetes (T1D) do not meet recommended glycemic targets, which are key for preventing adverse outcomes.1–6 Various automated insulin delivery systems are available and may allow for improved glycemic control and reduced treatment burden.7,8 The Omnipod 5 System uses a tubeless insulin pump, removing the need to disconnect tubing for certain activities,9 and its efficacy and safety has been demonstrated in clinical trials, and real-world effectiveness in diverse groups of patients with T1D.10–15 In this activity, learn from the experience of leading experts in T1D on how they used Omnipod 5 to manage a range of different patient cases.

Learning Objectives

After watching this activity, participants should be better able to:

  • Highlight key features of Omnipod 5 to support glycemic control in patients with Type 1 diabetes (T1D).
  • Demonstrate how Omnipod 5 can support the management of T1D across a range of real-world case studies.
  • Understand what features and resources are available to turn data into actionable insights and resources for clinicians.

References5

List View
Grid View
1

Tsushima Y, Galloway N. Glycemic Targets and Prevention of Complications. J Clin Endocrinol Metab. 2025;110(Supplement_2):S100–s11.

2

Arffman M, Hakkarainen P, Keskimäki I, Oksanen T, Sund R. Long-term and recent trends in survival and life expectancy for people with type 1 diabetes in Finland. Diabetes Res Clin Pract.  2023;198:110580.

3

Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66–72.

4

Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593–603.

5

World Health Organization. Measuring the global diabetes targets in the WHO European Region 2024. (Available from: https://diabetesatlas.org/media/uploads/sites/2/2024/10/J.Farrington_Measuring-the-Global-Diabetes-Targets.pdf)

Faculty & Disclosures4

Cari Berget

Barbara Davis Center Pediatrics, Aurora, CO
More Information
Close Popup

Cari Berget

Barbara Davis Center Pediatrics, Aurora, CO
US

Biography

Cari Berget is a registered nurse and certified diabetes care and education specialist at the Barbara Davis Center for Diabetes in Colorado. As part of her work, she manages the PANTHER pediatric artificial pancreas research program, which conducts clinical trials with patients with type 1 diabetes using advanced diabetes technologies. She has authored numerous peer reviewed publications, is a nationally recognized speaker on diabetes technology implementation.

Disclosures

Consulting/Speaker fees from Insulet, Dexcom and Embecta. Educational grants from Insulet and Tandem.

Severine Liabat

Dr Fiona Campbell

Dr Fiona Campbell

St. James’s University Hospital, Leeds
More Information
Close Popup

Dr Fiona Campbell

St. James’s University Hospital, Leeds
UK

Biography

Dr Fiona Campbell is a consultant paediatric diabetologist at St. James’s University Hospital, in Leeds, UK. Her work focuses on improving outcomes for young people with type 1 diabetes, with particular expertise in insulin pump therapy. She has served as Clinical Lead of the National Diabetes Quality Programme, chaired the National Children and Young People’s Diabetes Network, and contributed to multiple national steering groups shaping UK paediatric diabetes policy.

Disclosures

Speaker fees from Insulet. Lecturing and advisory board fees from Abbott Diabetes Care, Dexcom, Glooko/Diasend, Eli Lilly, Insulet, Medtronic and Novo Nordisk.

Cari Berget

Dr Jody Grundman

Dr Jody Grundman

Children’s National Hospital, Washington DC
More Information
Close Popup

Dr Jody Grundman

Children’s National Hospital, Washington DC
US

Biography

Jody Grundman is a paediatric endocrinologist at Children’s National Hospital in Washington, DC, specializing in type 1 diabetes. Her work centres on improving diabetes care for children and adolescents, with particular interest in addressing disparities in access and outcomes. She has authored peer reviewed research on diabetes management.

Disclosures

Speaker fees from Insulet. Advisory Board fees from Sanofi.

Dr Fiona Campbell

Severine Liabat

Severine Liabat

Medical affairs, Insulet International, Geneva
More Information
Close Popup

Severine Liabat

Medical affairs, Insulet International, Geneva
Switzerland

Biography

Severine Liabat is the Senior Director of Medical Affairs International at Insulet Corporation, where she leads strategy for tubeless insulin pump and automated insulin delivery technologies across global markets.

Disclosures

Speaker fees from Insulet.

Dr Jody Grundman

Cari Berget

Video Navigation

Video

Introduction

Activity overview and faculty introduction
Severine Liabat from Insulet provides a brief introduction to this activity on real-world case studies of Omnipod 5 use, and the faculty.
Start Time: 0:00

Important considerations for choosing an AID

Choosing an AID
Cari Berget introduces key features of the Omnipod 5 and clinical data supporting its use in patients with type 1 diabetes.
Start Time: 6:13

Case 1 – adult patient with T1D

Impact of Omnipod 5 in case 1
Cari Berget describes the impact of Omnipod 5 in an adult with type 1 diabetes and a history of inconsistent use of continuous glucose monitoring and carb counting.
Start Time: 16:49

Case 2 – adolescent patient with T1D

Impact of Omnipod 5 in case 2
Dr Fiona Campbell describes the impact of Omnipod 5 in an active adolescent with type 1 diabetes and a history achieving 90% or more time in glycemic range.
Start Time: 25:59

Case 3 – pediatric patient with T1D

Impact of Omnipod 5 in case 3
Dr Jody Grundman describes the impact of Omnipod 5 in a pediatric patient with type 1 diabetes and growth concerns from sub-optimal glycemic control.
Start Time: 44:50

Empowering clinicians and families

Resources
Severine Liabat provides insights into features of Omnipod 5 that can turn data into actionable insights, and resources for clinicians.
Start Time: 59:44

Add a Note

Note Time: 00:00
Save Note
touchENDOCRINOLOGY
touchMEETING HIGHLIGHTS

This content is intended for healthcare professionals in Australia, Belgium, Canada, France, Germany, Israel, Italy, Kuwait, Netherlands, Nordics, Qatar, Switzerland, UAE & UK only

Please confirm that you are a healthcare professional in one of those countries.

Continue
Decline

This Activity Is Sponsored By Insulet.

Insulet provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchENDOCRINOLOGY.

Close Popup
touchENDOCRINOLOGY

Could not verify Country/IP Address.

We were unable to verify your IP address, please try again later. If you are using a method to hide your IP address, such as a VPN or proxy, please disable this and try again.

Return to Homepage

This Activity Is Sponsored By Insulet.

Insulet provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchENDOCRINOLOGY.

Unapproved products or unapproved uses of approved products may be discussed; these situations may reflect the approval status in one or more jurisdictions. TMC has advised the sponsor to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by TMC of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in TMC activities. TMC accepts no responsibility for errors or omissions.

The views and opinions expressed are those of the faculty and do not necessarily reflect those of any sponsor.

Date of preparation: April 2026

Latest articles videos and clinical updates - straight to your inbox

Close Popup